THE MEDICVISION STORY
From Diagnostics to AI-Driven Eye Care Innovation
MedicVision AI was previously TBG Diagnostics Limited, a molecular diagnostics company listed on the Australian Securities Exchange.
In 2025, we recognized the opportunity to make a transformational impact in eye care by entering into strategic partnerships with Winston Medical Supply and Centre for Eye Research Australia (CERA).
The Vision that Changed Everything
We saw two critical gaps in the APAC eye care market—
Inherited retinal diseases like Usher Syndrome affect millions worldwide with no cure.
Advanced AI diagnostics and gene therapy could change this—but breakthrough research needed commercial pathways to reach patients.
Across Asia-Pacific, 90% of visual impairment is reventable, yet millions lack access to quality therapeutic solutions for conditions like pediatric myopia and dry eye disease.
Most companies choose one path or the other.
We chose both.
Mission
&
Values
Misson Statement
To transform eye care across the Asia-Pacific region by delivering accessible, high-quality therapeutic solutions and pioneering AI-enhanced diagnostic technologies that preserve and restore vision.
Our Values
Commitment to Excellence
We hold ourselves to the highest standards—from the partnerships we forge to the solutions we deliver. Australian TGA compliance isn't just regulatory necessity; it's our commitment to quality.
Our Startegic Partnerships
